EN DE
Watch Prodia Widyahusada Tbk PT for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Prodia Widyahusada Tbk PT (PRDA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Prodia Widyahusada Tbk PT stock IDR 4,426, price IDR 3,690, upside +20.0%, quality 76 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000138001

PW Prodia Widyahusada Tbk PT logo Thin data Nov 8, 2026

Prodia Widyahusada Tbk PT

PRDA · JK
Undervalued, in an uptrend

The stock costs 17% less than our calculation considers fair.

Fair value 4,426 IDR · Undervalued
Quality 76/100
Low debt
Generates free cash flow
4.4% dividend yield · Sustainable
Ranks above peers (14/14)
Mixed Growth (revenue 5y +4.0 %/yr in IDR)
Thin margins · 9.1% net margin (TTM)
Moderate moat 50/100 · thin data
Thin data
Watch Prodia Widyahusada Tbk PT for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

7,229 IDR 2,122 IDR Fair Value 4,426 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 2,122 IDR – 7,229 IDR · fair‑value band 3,658 IDR – 5,454 IDR · the 3,690 IDR price screens below the 4,426 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Prodia Widyahusada Tbk PT in your weekly email

Every Wednesday you see whether Prodia Widyahusada Tbk PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services.

Show moreShow less

It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia.

PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.

Stock analysis

Prodia Widyahusada Tbk PT (PRDA) currently trades at 3,690 IDR, while our model-based Fair Value estimate is 4,426 IDR, implying the stock looks roughly 17% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 5,045 IDR per share, and 17 of the 25 models we run sit above the 3,690 IDR price.

Bear case: the Asset-Based group reads lowest at 836.65 IDR, and 8 of the 25 models stay below the price. Data coverage for this calculation is low.

Scenario range: 3,658 IDR (bear) to 5,454 IDR (bull), the price of 3,690 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Prodia Widyahusada Tbk PT reported revenue of 2.3T IDR in FY2025 versus 2.7T IDR in FY2021, a compound −3.7%/yr. Reported net income was 207B IDR in FY2025, compounding −24.1%/yr from FY2021.

Key figures

Market cap 3.3T IDR (≈ $182M) Micro · P/E ratio 15.8 · P/S ratio 1.39 · EPS (TTM) 234.00 IDR · Dividend yield 4.4% · Net margin 9.1% · Return on equity 9.2% · Return on assets (EBIT) 15.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 20%, PRDA screens cheaper than that median.

Fair Value models

Bear 3,658 IDR Fair Value 4,426 IDR Bull 5,454 IDR
Price 3,690 IDR · Upside +20.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (61.16 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 3,637 IDR 4,499 IDR 5,475 IDR 82
Growth DCF 3,658 IDR 4,426 IDR 5,257 IDR 80
Owner Earnings 2,007 IDR 2,397 IDR 2,839 IDR 78
All 25 models by family
DCF Models
FCF DCF 3,637 IDR 4,499 IDR 5,475 IDR 82
Owner Earnings 2,007 IDR 2,397 IDR 2,839 IDR 78
5Y Revenue Exit 3,209 IDR 4,236 IDR 5,477 IDR 74
5Y EBITDA Exit 4,648 IDR 6,811 IDR 9,233 IDR 76
5Y P/E Exit 3,829 IDR 5,345 IDR 6,854 IDR 72
10Y Revenue Exit 3,339 IDR 4,186 IDR 5,202 IDR 68
10Y EBITDA Exit 4,125 IDR 5,617 IDR 7,455 IDR 69
10Y P/E Exit 3,703 IDR 4,803 IDR 6,028 IDR 65
Earnings-Based
Graham-Dodd 1,580 IDR 3,913 IDR 5,071 IDR 65
PEG = 1.0 709.30 IDR 1,013 IDR 1,317 IDR 57
EPV 1,933 IDR 2,075 IDR 2,189 IDR 74
Dividend Discount
Gordon GGM 1,190 IDR 1,794 IDR 2,322 IDR 69
DDM Multi-Stage 1,190 IDR 1,612 IDR 1,966 IDR 67
Multiples
P/E Multiple 3,835 IDR 5,113 IDR 6,391 IDR 63
P/S Multiple 2,963 IDR 3,951 IDR 4,939 IDR 58
P/B Multiple 4,225 IDR 5,634 IDR 7,042 IDR 55
EV/EBIT 3,893 IDR 4,978 IDR 6,063 IDR 66
EV/EBITDA 6,252 IDR 8,123 IDR 9,994 IDR 67
EV/Revenue 2,961 IDR 3,957 IDR 4,952 IDR 54
Asset-Based
NCAV (Graham) 552.19 IDR 836.65 IDR 1,046 IDR 54
Growth DCF
Growth DCF 3,658 IDR 4,426 IDR 5,257 IDR 80
Rev-Margin DCF 3,209 IDR 4,290 IDR 5,480 IDR 74
Economic Profit
Residual Income 2,026 IDR 2,121 IDR 2,299 IDR 76
ROIC Compounder 1,933 IDR 2,075 IDR 2,189 IDR 72
Growth Earnings
Growth-Adj P/E 2,937 IDR 4,195 IDR 5,454 IDR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 76/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 55
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 79
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 73
How calm the share price moves, does not count
Price momentum 87
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 96
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Start year 2020 (pandemic). Over 10 years: +6.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.5%
Dividend (yield on the price)4.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.5% vs 13.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −4.7% a year for the price.

Watch PRDA, get fair value alerts →

Compare Prodia Widyahusada Tbk PT with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 14/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside +20.0% · Top 25%
Profitability
Return on equity (12 months) 9.2% · Above median
Return on assets 7.7% · Top 25%
Net margin (12 months) 9.1% · Above median
Operating margin (12 months) 11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 12.7% · Above median
Dividend yield (12 months) 4.4% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 15.8× · Cheapest 25%
P/B 1.37× · Cheaper than median
P/S (12 months) 1.39× · Cheapest 25%
Price / free cash flow (fiscal year) 9.3× · Cheapest 25%
EV/EBITDA 7.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)60 · sector 0
FUTURE (revenue growth)64 · sector 39
PAST (return on equity)37 · sector 15
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)88 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs PRDA
IQVIA Holdings IQV $271.83 $299.01 +10% vs PRDA
Illumina, Inc ILMN $213.13 $234.44 +10% vs PRDA
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs PRDA
Danaher Corporation DHR $230.25 $209.18 −9% vs PRDA
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs PRDA
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs PRDA
Agilent Technologies, Inc A $174.76 $64.53 −63% vs PRDA
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs PRDA
Waters Corporation WAT $457.60 $91.26 −80% vs PRDA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prodia Widyahusada Tbk PT: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Prodia Widyahusada Tbk PT Fair Value". https://www.fairvalue-calculator.com/stock/PRDA

Frequently asked questions

Is Prodia Widyahusada Tbk PT (PRDA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 4,426 IDR versus a price of 3,690 IDR, about +20% upside (undervalued).
What is the fair value of PRDA?
Our model-based fair value for Prodia Widyahusada Tbk PT is 4,426 IDR (as of Nov 8, 2026), built from audited fundamentals. The current price: 3,690 IDR.
What is the quality score of PRDA?
Prodia Widyahusada Tbk PT has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prodia Widyahusada Tbk PT (PRDA)?
Our model-based price target is the fair value of 4,426 IDR (as of Nov 8, 2026) from 25 valuation models. Cautious scenario 3,658 IDR, optimistic scenario 5,454 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Prodia Widyahusada Tbk PT stock forecast for 2026?
Our models put fair value at 4,426 IDR, about +20% upside versus a price of 3,690 IDR (undervalued). Cautious scenario 3,658 IDR, optimistic scenario 5,454 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Prodia Widyahusada Tbk PT (PRDA)?
Prodia Widyahusada Tbk PT reported trailing-twelve-month revenue of about 2.4T IDR (latest available figure, as of Nov 8, 2026).
Does Prodia Widyahusada Tbk PT pay a dividend?
Prodia Widyahusada Tbk PT currently shows a dividend yield of 4.41% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Prodia Widyahusada Tbk PT (PRDA) and when is the ex-dividend date?
Prodia Widyahusada Tbk PT pays a dividend of 162.68 IDR per share a year, a dividend yield of 4.4%. The last ex-dividend date was May 5, 2026. A dividend has been paid every year since at least 2018. The payout ratio is 69.5% of earnings. Free cash flow covers the dividend 2.43 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Prodia Widyahusada Tbk PT (PRDA)?
For today's price to be fair in a discounted-cash-flow model, Prodia Widyahusada Tbk PT would have to grow free cash flow by -2.2 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.0 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of PRDA use?
Our models discount Prodia Widyahusada Tbk PT at 13.5 %: a base by market capitalisation (micro), damped by beta 0.03, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Prodia Widyahusada Tbk PT that is -2.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Prodia Widyahusada Tbk PT (PRDA) delivered so far?
Over the past 5 years revenue at Prodia Widyahusada Tbk PT grew +4.0 % a year. The price currently implies free-cash-flow growth of -2.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Prodia Widyahusada Tbk PT (PRDA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Prodia Widyahusada Tbk PT (-2.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Prodia Widyahusada Tbk PT (PRDA)?
The free-cash-flow yield on the price is 10.71 %: that much free cash flow Prodia Widyahusada Tbk PT produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Prodia Widyahusada Tbk PT (PRDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prodia Widyahusada Tbk PT it is 4,426 IDR per share (as of Nov 8, 2026), against a price of 3,690 IDR. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Prodia Widyahusada Tbk PT stock overvalued or undervalued in 2026?
As of Nov 8, 2026, PRDA trades below its calculated fair value: price 3,690 IDR, fair value 4,426 IDR, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRDA?
No. The price is what the market pays today (3,690 IDR); the fair value is what the company's own numbers justify (4,426 IDR). For Prodia Widyahusada Tbk PT the two are 736.39 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Prodia Widyahusada Tbk PT worth?
The market values Prodia Widyahusada Tbk PT at about 3.3T IDR (market capitalisation, as of Nov 8, 2026). Per share that is 3,690 IDR; our models calculate a fair value of 4,426 IDR per share.
What do the bullish and bearish scenarios say about PRDA?
Our models span a range for Prodia Widyahusada Tbk PT: cautious scenario 3,658 IDR, base 4,426 IDR, optimistic 5,454 IDR per share (as of Nov 8, 2026, price 3,690 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PRDA?
Prodia Widyahusada Tbk PT trades at a price-to-earnings ratio of 15.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4,426 IDR is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 14.1. Other multiples: P/B 1.4, P/S 1.4, EV/EBITDA 7.6.
How solid is the balance sheet of Prodia Widyahusada Tbk PT (PRDA)?
Balance-sheet figures for Prodia Widyahusada Tbk PT (as of Nov 8, 2026): return on equity 9.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is PRDA from its 52-week high?
Prodia Widyahusada Tbk PT trades at 3,690 IDR, about 1% below its 52-week high of 3,720 IDR and 71% above the low of 2,156 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4,426 IDR is for.
Which stocks are comparable to Prodia Widyahusada Tbk PT?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prodia Widyahusada Tbk PT stock attractive at the current price?
The data as of Nov 8, 2026: price 3,690 IDR, calculated fair value 4,426 IDR (+20%), Quality Score 76/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRDA calculated?
We run Prodia Widyahusada Tbk PT through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4,426 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Prodia Widyahusada Tbk PT currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prodia Widyahusada Tbk PT (PRDA)?
The closing price on Nov 6, 2026 was 3,690 IDR. Our model-based fair value is 4,426 IDR, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prodia Widyahusada Tbk PT right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Prodia Widyahusada Tbk PT (PRDA) come from?
Earnings per share at Prodia Widyahusada Tbk PT grew +14.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.4 %, EBIT margin +4.0 %, tax rate +0.5 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Prodia Widyahusada Tbk PT

How large is the market capitalisation of Prodia Widyahusada Tbk PT (PRDA)?
The market capitalisation of Prodia Widyahusada Tbk PT is 3.3T IDR (≈ $182M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prodia Widyahusada Tbk PT (PRDA)?
The price-to-sales ratio of Prodia Widyahusada Tbk PT is 1.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prodia Widyahusada Tbk PT (PRDA)?
Earnings per share at Prodia Widyahusada Tbk PT are 234.00 IDR (price ÷ EPS = P/E 15.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Prodia Widyahusada Tbk PT (PRDA)?
The dividend yield of Prodia Widyahusada Tbk PT is 4.4% (payout 69.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Prodia Widyahusada Tbk PT (PRDA)?
The net margin of Prodia Widyahusada Tbk PT is 9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Prodia Widyahusada Tbk PT (PRDA)?
The return on equity (ROE) of Prodia Widyahusada Tbk PT is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prodia Widyahusada Tbk PT (PRDA)?
On an EBIT basis the return on assets of Prodia Widyahusada Tbk PT is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prodia Widyahusada Tbk PT (PRDA)?
The operating margin of Prodia Widyahusada Tbk PT is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prodia Widyahusada Tbk PT (PRDA)?
Revenue at Prodia Widyahusada Tbk PT is growing +12.7% versus a year earlier (3y avg +1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Prodia Widyahusada Tbk PT (PRDA)?
Earnings per share at Prodia Widyahusada Tbk PT are growing −3.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Prodia Widyahusada Tbk PT (PRDA) hold?
Prodia Widyahusada Tbk PT holds more cash than debt, 568B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Prodia Widyahusada Tbk PT in the live analysis

One click puts Prodia Widyahusada Tbk PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.